SCHEMBL5459294

SCHEMBL5459294

CC(C)(C)c1cc(S(=O)(=O)Cc2ccc(Cl)cc2)cc(C(C)(C)C)c1O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.40
PKM P14618 1/20 0.40
CYP3A4 P08684 3/20 0.40
RECQL P46063 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
KMT2A Q03164 5/20 0.39
ALDH1A1 P00352 5/20 0.39
MEN1 O00255 4/20 0.39
TSHR P16473 3/20 0.39
CYP1A2 P05177 2/20 0.39
MAPK1 P28482 2/20 0.39
BLM P54132 2/20 0.39
ATM Q13315 2/20 0.39
HIF1A Q16665 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
USP2 O75604 1/20 0.39
CYP2D6 P10635 1/20 0.39
GAA P10253 2/20 0.38
LMNA P02545 2/20 0.38
CA2 P00918 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5463544 0.87 MLNR (0.47) MAPTCYP3A4RECQLKMT2AALDH1A1
SCHEMBL5465687 0.85 MAOA (0.39) MAPTCYP3A4L3MBTL1KMT2AALDH1A1
SCHEMBL5456600 0.83 MEN1 (0.45) MAPTKMT2AMEN1TSHRGAA
SCHEMBL5450686 0.83 MEN1 (0.45) MAPTKMT2AMEN1TSHRGAA
SCHEMBL5461655 0.80 PTGS2 (0.50) KMT2AMEN1GAAGABBR2GABBR1
SCHEMBL5465032 0.80 TXNRD1 (0.44) ALDH1A1CA2CA1RAB9ATP53
SCHEMBL5461659 0.80 PTGS2 (0.50) KMT2AMEN1GAAGABBR2GABBR1
SCHEMBL4116222 0.77 GLRA3 (0.46) CYP3A4KMT2AALDH1A1MEN1TSHR
SCHEMBL5450665 0.76 RIPK1 (0.41) MAPTCYP3A4KMT2AALDH1A1MEN1
SCHEMBL5450671 0.74 ESR2 (0.44) MAPTKMT2AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070004799-A1 Novel compounds for the treatment of obesity NOVO NORDISK A/S (DK) 2007-01-04 US claimed
EP-1689707-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-08-16 EP claimed
WO-2005051900-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2005-06-09 WO claimed
US-20070004799-A1 Novel compounds for the treatment of obesity NOVO NORDISK A/S (DK) 2007-01-04 US disclosed
US-20070004799-A1 Novel compounds for the treatment of obesity NOVO NORDISK A/S (DK) 2007-01-04 US disclosed
US-20070004799-A1 Novel compounds for the treatment of obesity NOVO NORDISK A/S (DK) 2007-01-04 US disclosed
EP-1689707-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2006-08-16 EP disclosed
WO-2005051900-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF OBESITY NOVO NORDISK A/S (DK) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004799-A1 Novel compounds for the treatment of obesity GPR119, NR4A3, NR4A1 MAPT 4875/4885PKM 4484/4885CYP3A4 469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.